Slingshot members are tracking this event:
Xenon (XENE) Expands Ion Channel Neurology Pipeline with Addition of XEN496, a “Phase 3 Ready” Potassium Channel Modulator for the Treatment of Epilepsy
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Ezogabine, also known as retigabine, is the only anti-epileptic drug previously approved by the FDA with a mechanism of action that potentiates Kv7-mediated potassium current. Ezogabine was originally approved by the FDA in June 2011 as an adjunctive treatment for adults with focal seizures with or without secondary generalization. GlaxoSmithKline (GSK) marketed ezogabine in various jurisdictions – as Potiga® in the U.S.and Trobalt™ in Europe – but withdrew the drug from the market worldwide in June 2017 citing commercial reasons.
Slingshot Insights Explained
Sep 06, 2018
Don’t see a project related to the catalyst you care about?
Related Keywords Ion Channel Activator, Xen496, Potassium Channel Modulator, Epilepsy